Management of Stage I Seminomatous Testicular Cancer: a Systematic Review

Clinical Oncology

Volumn 22, Issue 1, 2010, Pages 6-16

  Chung, P ^a   Mayhew, L A ^b   Warde, P ^a   Winquist, E ^c   Lukka, H ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Adjuvant chemotherapy; adjuvant radiation therapy; seminoma; surveillance; systematic review; testicular neoplasms

Indexed keywords

CARBOPLATIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DYSPEPSIA; HUMAN; LETHARGY; LONG TERM CARE; MULTIPLE CYCLE TREATMENT; ORCHIECTOMY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION FIELD; RISK ASSESSMENT; SECOND CANCER; SEMINOMA; SEXUAL FUNCTION; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

HUMANS; MALE; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 73149105939     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2009.08.006     Document Type: Article

References (67)

1. National Cancer Institute of Canada. Canadian cancer statistics 2009 (2009), National Cancer Institute of Canada, Toronto
2. Weir H.K., Marrett L.D., and Moravan V. Trends in the incidence of testicular germ cell cancer in Ontario by histologic subgroup, 1964-1996. CMAJ 160 (1999) 201-205
3. McGlynn K.A., Devesa S.S., Sigurdson A.J., et al. Trends in the incidence of testicular germ cell tumors in the United States. Cancer 97 (2003) 63-70
4. Warde P.R., Sturgeon J.F.G., and Gospodarowiz M.K. Testicular cancer. In: Gunderson L.L., and Tepper J.E. (Eds). Clinical radiation oncology. 2nd edn (2007), Churchill Livingstone, New York 1261-1285
5. Choo R., Sandler H., Warde P., et al. Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States. Can J Urol 9 (2002) 1479-1485
6. Alomary I., Samant R., Genest P., et al. The preferred treatment for stage I seminoma: a survey of Canadian radiation oncologists. Clin Oncol (R Coll Radiol) 18 (2006) 696-699
7. Chung P., Mayhew L.A., Warde P., Winquist E., Lukka H., and Genitourinary Disease Site Group. Management of stage I seminoma. Program in Evidence-Based Care Evidence Based Series no. 3-18 (2008), Cancer Care Ontario, Toronto. Available from: http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=14044 [accessed 13.07.09]
8. Higgins J, Green S, editors. Approaches to summarising the validity of studies. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Section 6.7. Chichester: John Wiley & Sons. Available from http://www.cochrane.org/resources/handbook/hbook.htm [accessed 01.03.06]
9. The AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003;12(1):18-23.
10. Shelley M.D., Burgon K., and Mason M.D. Treatment of testicular germ-cell cancer: a Cochrane evidence-based systematic review. Cancer Treat Rev 28 (2002) 237-253
11. Krege S., Souchon R., and Schmoll H.J. Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors: result of an update conference on evidence-based medicine (EBM). Eur Urol 40 (2001) 372-391
12. National Institute for Health and Clinical Excellence (NICE). Improving outcomes in urological cancers - manual, UK, 2002. Available from:. http://guidance.nice.org.uk/CSGUC/Guidance/pdf/English [accessed 16.07.09]
13. National Institute for Health and Clinical Excellence. Improving outcomes in urological cancers - Research evidence, UK, 2002. Available from:. http://guidance.nice.org.uk/index.jsp?action=download&o=28772 [accessed 16.07.09]
14. Schmoll H.J., Souchon R., Krege S., et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15 (2004) 1377-1399
15. Albers P., Albrecht W., Algaba F., et al. Guidelines on testicular cancer. Eur Urol 48 (2005) 885-894
16. Wood L., Wilke D., Rutledge R., et al. Guidelines for the management of adult testicular cancer. Genitourinary Cancer Site Team, Cancer Care Nova Scotia, 2004 (revised 2005). Available from:. http://www.cancercare.ns.ca/site-cc/media/cancercare/TesticularGuidelinesREV2006(1).pdf [accessed 16.07.09]
17. Motzer R.J., Bahnson R.R., Boston B., et al. Testicular cancer. Clinical practice guidelines. J Natl Compr Canc Netw 3 (2005) 52-76
18. Martin J.M., Panzarella T., Zwahlen D.R., et al. Evidence-based guidelines for following stage 1 seminoma. Cancer 109 (2007) 2248-2256
19. Jones W.G., Fossa S.D., Mead G.M., et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23 (2005) 1200-1208
20. Fossa S.D., Horwich A., Russell J.M., et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 17 (1999) 1146
21. Oliver R.T., Mason M.D., Mead G.M., et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366 (2005) 293-300
22. Bamberg M., Schmidberger H., Meisner C., et al. Radiotherapy for stages I and IIA/B testicular seminoma. Int J Cancer 83 (1999) 823-827
23. Classen J., Schmidberger H., Meisner C., et al. Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German Testicular Cancer Study Group (GTCSG). Br J Cancer 90 (2004) 2305-2311
24. Livsey J.E., Taylor B., Mobarek N., et al. Patterns of relapse following radiotherapy for stage I seminoma of the testis: implications for follow-up. Clin Oncol (R Coll Radiol) 13 (2001) 296-300
25. Logue J.P., Harris M.A., Livsey J.E., et al. Short course para-aortic radiation for stage I seminoma of the testis. Int J Radiat Oncol Biol Phys 57 (2003) 1304-1309
26. Niewald M., Waziri A., Walter K., et al. Low-dose radiotherapy for stage I seminoma: early results. Radiother Oncol 37 (1995) 164-166
27. Niewald M., Freyd J., Fleckenstein J., et al. Low-dose radiotherapy for stage I seminoma-long-term results. Int J Radiat Oncol Biol Phys 66 (2006) 1112-1119
28. Sommer K., Brockman W.P., and Hubener K.H. Treatment results and acute and late toxicity of radiation therapy for testicular seminoma. Cancer 66 (1990) 259-263
29. Taylor M.B., Carrington B.M., Livsey J.E., et al. The effect of radiotherapy treatment changes on sites of relapse in stage I testicular seminoma. Clin Radiol 56 (2001) 116-119
30. Argirovic D. Germ cell testicular tumors in clinical stage A and normal values of serum tumor markers post-orchiectomy: the experience in the management of 300 consecutive patients. J BUON 10 (2005) 195-200
31. Dieckmann K.P., Bruggeboes B., Pichlmeier U., et al. Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient?. Urology 55 (2000) 102-106
32. Powles T., Oliver T., Ostrowski M., et al. The long term side effects of adjuvant carboplatin for stage I seminoma. J Clin Oncol 25 Suppl. (2007) 5089
33. Reiter W.J., Brodowicz T., Alavi S., et al. Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol 19 (2001) 101-104
34. Steiner H., Holtl L., Wirtenberger W., et al. Long-term experience with carboplatin monotherapy for clinical stage I seminoma: a retrospective single-center study. Urology 60 (2002) 324-328
35. Powles T., Robinson D., Shamash J., et al. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 19 (2008) 407-408
36. Daugaard G., Petersen P.M., and Rorth M. Surveillance in stage I testicular cancer. APMIS 111 (2003) 76-83
37. Francis R., Bower M., Brunstrom G., et al. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur J Cancer 36 (2000) 1925-1932
38. Horwich A., Alsanjari N., A'Hern R., et al. Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 65 (1992) 775-778
39. Warde P.R., Gospodarowicz M.K., Goodman P.J., et al. Results of a policy of surveillance in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 27 (1993) 11-15
40. Horwich A., Dearnaley D., Parker C., and Huddart R. Treatment burden following surveillance for stage 1 seminoma of the testis. American Society for Clinical Oncology. 2008 Genitourinary Cancers Symposium. Available from:. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=54&abstractID=20237
41. Alomary I., Samant R., and Gallant V. Treatment of stage I seminoma: a 15-year review. Urol Oncol 24 (2006) 180-183
42. Oliver R.T., Edmonds P.M., Ong J.Y., et al. Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy?. Int J Radiat Oncol Biol Phys 29 (1994) 3-8
43. Warde P., Gospodarowicz M.K., Panzarella T., et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 13 (1995) 2255-2262
44. Warde P., Gospodarowicz M.K., Panzarella T., et al. Long term outcome and cost in the management of stage I testicular seminoma. Can J Urol 7 (2000) 967-972
45. Warde P., Chung P., Sturgeon J., et al. Should surveillance be considered the standard of care in stage I seminoma?. J Clin Oncol 23 Suppl. (2005) 4520
46. Aparicio J., Garcia del Muro X., Maroto P., et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 14 (2003) 867-872
47. Aparicio J., Germa J.R., Garcia del Muro X., et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 23 (2005) 8717-8723
48. Bokemeyer C., and Schmoll H.J. Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 11 (1993) 1703-1709
49. Hay J.H., Duncan W., and Kerr G.R. Subsequent malignancies in patients irradiated for testicular tumours. Br J Radiol 57 (1984) 597-602
50. Horwich A., and Bell J. Mortality and cancer incidence following radiotherapy for seminoma of the testis. Radiother Oncol 30 (1994) 193-198
51. Jacobsen G.K., Mellemgaard A., Engelholm S.A., et al. Increased incidence of sarcoma in patients treated for testicular seminoma. Eur J Cancer 29A (1993) 664-668
52. Moller H., Mellemgaard A., Jacobsen G.K., et al. Incidence of second primary cancer following testicular cancer. Eur J Cancer 29A (1993) 672-676
53. Richiardi L., Scelo G., Boffetta P., et al. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer 120 (2007) 623-631
54. Robinson D., Moller H., and Horwich A. Mortality and incidence of second cancers following treatment for testicular cancer. Br J Cancer 96 (2007) 529-533
55. Travis L.B., Curtis R.E., Storm H., et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89 (1997) 1429-1439
56. Travis L.B., Fossa S.D., Schonfeld S.J., et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97 (2005) 1354-1365
57. van Leeuwen F.E., Stiggelbout A.M., van den Belt-Dusebout A.W., et al. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol 11 (1993) 415-424
58. Vudarla N., Jawed I., Kaya H., et al. Survival and secondary malignancy rates for adjuvant radiation therapy versus observation in stage I testicular seminoma: a Surveillance, Epidemiology, and End Results (SEER) analysis. J Clin Oncol 25 Suppl. (2007) 5020
59. Wanderas E.H., Fossa S.D., and Tretli S. Risk of a second germ cell cancer after treatment of a primary germ cell cancer in 2201 Norwegian male patients. Eur J Cancer 33 (1997) 244-252
60. Huddart R.A., Norman A., Shahidi M., et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21 (2003) 1513-1523
61. Zagars G.K., Ballo M.T., Lee A.K., et al. Mortality after cure of testicular seminoma. J Clin Oncol 22 (2004) 640-647
62. Schoffski P., Hohn N., Kowalski R., et al. Health-related quality of life (QoL) in patients with seminoma stage I treated with either adjuvant radiotherapy (RT) or two cycles of carboplatinum chemotherapy (CT): results of a randomized phase III trial of the German Interdisciplinary Working Party on Testicular Cancer. J Clin Oncol 25 Suppl. (2007) 5050
63. Mead G.M., Fossa S.D., Oliver R.T., et al. Relapse patterns in 2,466 stage 1 seminoma patients (pts) entered into Medical Research Council randomised trials. J Clin Oncol 26 Suppl. (2008) 5020
64. Oliver R.T., Mead G.M., Fogarty P.J., and Stenning S.P. MRC TE19 and EORTC 30982 trial collaborators. Radiotherapy versus carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214). J Clin Oncol 26 Suppl. (2008) 1
65. Brenner DJ, Hall EJ. Computed tomography - an increasing source of radiation exposure. N Engl J Med 2007;57: 2277-2284.
66. Little MP, Wakeford R, Tawn EJ, et al. Risks associated with low doses and low dose rates of ionizing radiation: why linearity may be (almost) the best that we can do. Radiology 2009;251:6-12.
67. Tubiana M, Feinendegan LE, Yang C, et al. The linear no-threshold relationship is inconsistent with radiation biologic and experimental data. Radiology 2009;251:13-22.